Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Suppression of Ovarian Cancer Cell Proliferation is Associated with Upregulation of Cell-Matrix Adhesion Programs and Integrin-β4-Induced Cell Protection from Cisplatin.

bioRxiv : the preprint server for biology·2025

Same author

Suppression of Ovarian Cancer Cell Proliferation Is Associated with Upregulation of Cell-Matrix Adhesion Programs and Integrin-β4-Induced Cell Protection from Cisplatin.

Cancers·2025

Same author

Serotonin-2 Receptor Agonists Produce Anti-inflammatory Effects through Functionally Selective Mechanisms That Involve the Suppression of Disease-Induced Arginase 1 Expression.

ACS pharmacology & translational science·2024

Same author

Elucidating host cell response pathways and repurposing therapeutics for SARS-CoV-2 and other coronaviruses.

Scientific reports·2022

Same author

Development of the Digital Arthritis Index, a Novel Metric to Measure Disease Parameters in a Rat Model of Rheumatoid Arthritis.

Frontiers in pharmacology·2017

Same author

Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization.

Nature genetics·2014

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

In Silico Clinical Trials for Cardiovascular Disease

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

Genomics and cardiovascular drug development.

Andrew S Plump¹, Pek Yee Lum

¹Cardiovascular Diseases, Merck Research Laboratories, Rahway, New Jersey 07065, USA. andrew_plump@merck.com

Journal of the American College of Cardiology

|March 28, 2009

Summary

Genomic research revolutionizes cardiovascular drug development, identifying novel targets to address the 70% residual risk in atherosclerotic heart disease, a leading cause of death.

More Related Videos

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

Related Experiment Videos

Last Updated: Jun 24, 2026

In Silico Clinical Trials for Cardiovascular Disease

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

Area of Science:

Cardiovascular Research
Genomics
Drug Development

Background:

Cardiovascular disease (CVD) is the leading cause of death globally, with significant residual risk despite statin therapy.
Few novel cardiovascular therapies have emerged since statins became available in 1987.
A 70% residual risk in atherosclerotic heart disease highlights the urgent need for innovative treatments.

Purpose of the Study:

To review the application of genomics in developing novel atherosclerosis therapies.
To explore how genomic advancements can accelerate cardiovascular drug discovery.
To discuss the potential of genomics in identifying new therapeutic targets and biomarkers.

Main Methods:

Review of advancements in genomic research, including genome-wide genotyping and gene expression profiling.
Integration of proteomic and metabolomic methodologies.
Application of systems biology approaches through advanced informatics.

Main Results:

Genomic approaches are actively identifying and validating novel targets for drug development pipelines.
Genomics promises to enhance biomarker discovery and patient segmentation for targeted therapies.
The genomics revolution is paving the way for next-generation cardiovascular treatments.

Conclusions:

Genomics offers a powerful toolkit to overcome limitations of current cardiovascular therapies.
Continued application of genomic strategies is crucial for developing effective atherosclerosis treatments.
Future cardiovascular drug development will be significantly shaped by genomic insights.